{"transactions":[{"id":784539,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Warrants (Right to Buy)","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":false,"shares":28800,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":0,"derivative":{"exercise_price":0.1,"underlying":"Common Stock","underlying_shares":2963},"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784538,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-07","kind":"grant","planned":false,"acquired":true,"shares":626220,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Option will vest in full on May 7, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":626220,"derivative":{"exercise_price":18,"expiration_date":"2036-05-06","underlying":"Common Stock","underlying_shares":626220},"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784537,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series D Convertible Preferred Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":false,"shares":96002,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9880},"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784536,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":false,"shares":100000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10291},"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784535,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":false,"shares":79166,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8527},"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784534,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"tax_withholding","planned":false,"acquired":false,"shares":17,"price":18,"value":306.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis."},{"field":"shares","element":"transactionShares","label":"F6","text":"Pursuant to the terms of the warrants, the Issuer withheld 17 warrant shares to pay the exercise price in connection with the net exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":31644,"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784533,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":true,"shares":2963,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The warrants to purchase shares of Common Stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":31661,"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784532,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-11","kind":"exercise","planned":false,"acquired":true,"shares":28698,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These securities are held of record by Racing Beach Ventures LLC (\"Racing Beach\"). The Reporting Person is a managing member of Racing Beach and may be deemed to have beneficial ownership of the securities."}],"balance_after":28698,"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":784531,"issuer":{"id":4850,"kind":"organization","name":"Odyssey Therapeutics, Inc."},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-12T00:35:18.000Z","date":"2026-05-08","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":20,"value":100000.0,"ownership":{"direct":true},"balance_after":270198,"source":{"system":"sec-edgar","filing":"0001193125-26-217607","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1242825/000119312526217607/ownership.xml","form_type":"4"}},{"id":312719,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-02-26T23:11:08.000Z","date":"2026-02-24","kind":"tax_withholding","planned":false,"acquired":false,"shares":3547,"price":485.11,"value":1720685.17,"ownership":{"direct":true},"balance_after":34797,"source":{"system":"sec-edgar","filing":"0001242825-26-000002","document":"wk-form4_1772147464.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000124282526000002/wk-form4_1772147464.xml","form_type":"4"}},{"id":313137,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-02-19T21:18:51.000Z","date":"2026-02-18","kind":"tax_withholding","planned":false,"acquired":false,"shares":2964,"price":483.75,"value":1433835.0,"ownership":{"direct":true},"balance_after":38344,"source":{"system":"sec-edgar","filing":"0000875320-26-000092","document":"wk-form4_1771535929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000092/wk-form4_1771535929.xml","form_type":"4"}},{"id":313136,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-02-19T21:18:51.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":8269,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":41308,"source":{"system":"sec-edgar","filing":"0000875320-26-000092","document":"wk-form4_1771535929.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000092/wk-form4_1771535929.xml","form_type":"4"}},{"id":314830,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2026-01-26T21:28:06.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":9012,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/24/2026."}],"balance_after":33039,"source":{"system":"sec-edgar","filing":"0000875320-26-000020","document":"wk-form4_1769462884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532026000020/wk-form4_1769462884.xml","form_type":"4"}},{"id":316525,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-04","kind":"exercise","planned":true,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316524,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":false,"shares":63781,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"Fully vested."}],"balance_after":0,"derivative":{"exercise_price":86.52,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":63781},"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316523,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-04","kind":"exercise","planned":true,"acquired":true,"shares":1,"price":91.05,"value":91.05,"ownership":{"direct":true},"balance_after":24027,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316522,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":2070,"price":455.22,"value":942305.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"Open market sales reported on this line occurred at a weighted average price of $455.22 (range $454.88 to $455.66)."}],"balance_after":24026,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316521,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":10360,"price":453.34,"value":4696602.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Open market sales reported on this line occurred at a weighted average price of $453.34 (range $452.91 to $453.70)."}],"balance_after":26096,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316520,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":15681,"price":452.2,"value":7090948.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Open market sales reported on this line occurred at a weighted average price of $452.20 (range $451.73 to $452.69)."}],"balance_after":36456,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316519,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":5809,"price":451.2,"value":2621020.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Open market sales reported on this line occurred at a weighted average price of $451.20 (range $450.71 to $451.70)."}],"balance_after":52137,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316518,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":5880,"price":449.84,"value":2645059.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $449.84 (range $449.22 to $450.18)."}],"balance_after":57946,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316517,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":2320,"price":448.78,"value":1041169.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $448.78 (range $448.18 to $449.12)."}],"balance_after":63826,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316516,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":1152,"price":447.05,"value":515001.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $447.05 (range $447.00 to $447.23)."}],"balance_after":66146,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316515,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":7899,"price":445.56,"value":3519478.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $445.56 (range $445.00 to $445.82)."}],"balance_after":67298,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316514,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":4352,"price":444.36,"value":1933854.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $444.36 (range $444.00 to $444.94)."}],"balance_after":75197,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316513,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":2469,"price":443.21,"value":1094285.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $443.21 (range $442.94 to $443.93)."}],"balance_after":79549,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316512,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":1320,"price":441.26,"value":582463.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $441.26 (range $441.14 to $442.00)."}],"balance_after":82018,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316511,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"sale","planned":true,"acquired":false,"shares":4469,"price":440.4,"value":1968147.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $440.40 (range $440.04 to $441.00)."}],"balance_after":83338,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":316510,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-12-05T21:10:39.000Z","date":"2025-12-03","kind":"exercise","planned":true,"acquired":true,"shares":63781,"price":86.52,"value":5518332.12,"ownership":{"direct":true},"balance_after":87807,"source":{"system":"sec-edgar","filing":"0000875320-25-000242","document":"wk-form4_1764969035.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000242/wk-form4_1764969035.xml","form_type":"4"}},{"id":317095,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":false,"shares":39769,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":63781,"derivative":{"exercise_price":86.52,"expiration_date":"2027-02-02","underlying":"Common Stock","underlying_shares":39769},"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317094,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":false,"shares":13835,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":1,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":13835},"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317093,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":false,"shares":19688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Fully vested."}],"balance_after":13836,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":19688},"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317092,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":40,"price":442,"value":17680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."}],"balance_after":24026,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317091,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":21330,"price":441.35,"value":9413995.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $441.35 (range $441.00 to $441.99)."}],"balance_after":24066,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317090,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"sale","planned":true,"acquired":false,"shares":32234,"price":440.3,"value":14192630.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $440.30 (range $440.00 to $440.99)."}],"balance_after":45396,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317089,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":true,"shares":39769,"price":86.52,"value":3440813.88,"ownership":{"direct":true},"balance_after":77630,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317088,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-14","kind":"exercise","planned":true,"acquired":true,"shares":13835,"price":91.05,"value":1259676.75,"ownership":{"direct":true},"balance_after":37861,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317087,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":1160,"price":441.05,"value":511618.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $441.05 (range $441.00 to $441.10)."}],"balance_after":24026,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317086,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-13","kind":"sale","planned":true,"acquired":false,"shares":18528,"price":440.22,"value":8156396.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 8/6/2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $440.22 (range $440.00 to $440.99)."}],"balance_after":25186,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":317085,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-11-17T21:12:06.000Z","date":"2025-11-13","kind":"exercise","planned":true,"acquired":true,"shares":19688,"price":91.05,"value":1792592.4,"ownership":{"direct":true},"balance_after":43714,"source":{"system":"sec-edgar","filing":"0000875320-25-000234","document":"wk-form4_1763413922.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000234/wk-form4_1763413922.xml","form_type":"4"}},{"id":325782,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-02-19T21:33:34.000Z","date":"2025-02-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":6066,"price":463.46,"value":2811348.36,"ownership":{"direct":true},"balance_after":24026,"source":{"system":"sec-edgar","filing":"0000875320-25-000091","document":"wk-form4_1740000808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000091/wk-form4_1740000808.xml","form_type":"4"}},{"id":326067,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-02-14T21:17:12.000Z","date":"2025-02-13","kind":"tax_withholding","planned":false,"acquired":false,"shares":2525,"price":450.83,"value":1138345.75,"ownership":{"direct":true},"balance_after":30092,"source":{"system":"sec-edgar","filing":"0000875320-25-000071","document":"wk-form4_1739567825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000071/wk-form4_1739567825.xml","form_type":"4"}},{"id":326066,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-02-14T21:17:12.000Z","date":"2025-02-12","kind":"grant","planned":false,"acquired":true,"shares":7209,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":32617,"source":{"system":"sec-edgar","filing":"0000875320-25-000071","document":"wk-form4_1739567825.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000071/wk-form4_1739567825.xml","form_type":"4"}},{"id":326550,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2025-02-06T21:38:57.000Z","date":"2025-02-04","kind":"grant","planned":false,"acquired":true,"shares":15414,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/17/2025."}],"balance_after":25408,"source":{"system":"sec-edgar","filing":"0000875320-25-000020","document":"wk-form4_1738877930.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000020/wk-form4_1738877930.xml","form_type":"4"}},{"id":330922,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-09-04T20:13:31.000Z","date":"2024-08-30","kind":"sale","planned":true,"acquired":false,"shares":3784,"price":499,"value":1888216.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2024."}],"balance_after":9994,"source":{"system":"sec-edgar","filing":"0000875320-24-000212","document":"wk-form4_1725480803.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000212/wk-form4_1725480803.xml","form_type":"4"}},{"id":339691,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-21T21:34:10.000Z","date":"2024-02-20","kind":"tax_withholding","planned":false,"acquired":false,"shares":4118,"price":420.58,"value":1731948.44,"ownership":{"direct":true},"balance_after":13778,"source":{"system":"sec-edgar","filing":"0000875320-24-000076","document":"wk-form4_1708551231.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000076/wk-form4_1708551231.xml","form_type":"4"}},{"id":340150,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-16T21:07:03.000Z","date":"2024-02-15","kind":"sale","planned":true,"acquired":false,"shares":4655,"price":419.16,"value":1951189.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."}],"balance_after":17896,"source":{"system":"sec-edgar","filing":"0000875320-24-000064","document":"wk-form4_1708117602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000064/wk-form4_1708117602.xml","form_type":"4"}},{"id":340149,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-16T21:07:03.000Z","date":"2024-02-14","kind":"sale","planned":true,"acquired":false,"shares":4356,"price":419.04,"value":1825338.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $419.04 (range $419.00 to $419.38)."}],"balance_after":22551,"source":{"system":"sec-edgar","filing":"0000875320-24-000064","document":"wk-form4_1708117602.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000064/wk-form4_1708117602.xml","form_type":"4"}},{"id":340363,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-14T21:04:31.000Z","date":"2024-02-13","kind":"sale","planned":true,"acquired":false,"shares":737,"price":419.13,"value":308898.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $419.13 (range $419.00 to $419.37)."}],"balance_after":26907,"source":{"system":"sec-edgar","filing":"0000875320-24-000059","document":"wk-form4_1707944646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000059/wk-form4_1707944646.xml","form_type":"4"}},{"id":340362,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-14T21:04:31.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":647,"price":420.39,"value":271992.33,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94)."}],"balance_after":27644,"source":{"system":"sec-edgar","filing":"0000875320-24-000059","document":"wk-form4_1707944646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000059/wk-form4_1707944646.xml","form_type":"4"}},{"id":340361,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-14T21:04:31.000Z","date":"2024-02-12","kind":"sale","planned":true,"acquired":false,"shares":2009,"price":419.22,"value":842212.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71)."}],"balance_after":28291,"source":{"system":"sec-edgar","filing":"0000875320-24-000059","document":"wk-form4_1707944646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000059/wk-form4_1707944646.xml","form_type":"4"}},{"id":340662,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-12T21:08:48.000Z","date":"2024-02-09","kind":"tax_withholding","planned":false,"acquired":false,"shares":8048,"price":422.74,"value":3402211.52,"ownership":{"direct":true},"balance_after":30300,"source":{"system":"sec-edgar","filing":"0000875320-24-000037","document":"wk-form4_1707772116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000037/wk-form4_1707772116.xml","form_type":"4"}},{"id":340661,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-12T21:08:48.000Z","date":"2024-02-08","kind":"tax_withholding","planned":false,"acquired":false,"shares":2698,"price":421.73,"value":1137827.54,"ownership":{"direct":true},"balance_after":38348,"source":{"system":"sec-edgar","filing":"0000875320-24-000037","document":"wk-form4_1707772116.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000037/wk-form4_1707772116.xml","form_type":"4"}},{"id":341071,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-08T21:40:41.000Z","date":"2024-02-07","kind":"grant","planned":false,"acquired":true,"shares":7707,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":41046,"source":{"system":"sec-edgar","filing":"0000875320-24-000028","document":"wk-form4_1707428432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000028/wk-form4_1707428432.xml","form_type":"4"}},{"id":341070,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-08T21:40:41.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":20452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/10/2024."}],"balance_after":33339,"source":{"system":"sec-edgar","filing":"0000875320-24-000028","document":"wk-form4_1707428432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000028/wk-form4_1707428432.xml","form_type":"4"}},{"id":341069,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-02-08T21:40:41.000Z","date":"2024-02-06","kind":"grant","planned":false,"acquired":true,"shares":10464,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation\ncommittee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024."}],"balance_after":12887,"source":{"system":"sec-edgar","filing":"0000875320-24-000028","document":"wk-form4_1707428432.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000028/wk-form4_1707428432.xml","form_type":"4"}},{"id":342606,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2024-01-10T21:06:40.000Z","date":"2024-01-08","kind":"sale","planned":true,"acquired":false,"shares":6648,"price":419.07,"value":2785977.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $419.07 (range $419.00 to $419.21)."}],"balance_after":2423,"source":{"system":"sec-edgar","filing":"0000875320-24-000004","document":"wk-form4_1704920790.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532024000004/wk-form4_1704920790.xml","form_type":"4"}},{"id":343617,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-12-15T21:33:17.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":100,"price":400.19,"value":40019.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."}],"balance_after":9071,"source":{"system":"sec-edgar","filing":"0000875320-23-000060","document":"wk-form4_1702675985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000060/wk-form4_1702675985.xml","form_type":"4"}},{"id":343616,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-12-15T21:33:17.000Z","date":"2023-12-13","kind":"sale","planned":true,"acquired":false,"shares":13254,"price":399.41,"value":5293780.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $399.41 (range $399.00 to $399.97)."}],"balance_after":9171,"source":{"system":"sec-edgar","filing":"0000875320-23-000060","document":"wk-form4_1702675985.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000060/wk-form4_1702675985.xml","form_type":"4"}},{"id":345092,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-10-18T20:17:15.000Z","date":"2023-10-16","kind":"sale","planned":true,"acquired":false,"shares":12962,"price":374,"value":4847788.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $374.00 (range $374.00 to $374.02)."}],"balance_after":22425,"source":{"system":"sec-edgar","filing":"0001209191-23-053073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123053073/doc4.xml","form_type":"4"}},{"id":349336,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-09T20:10:59.000Z","date":"2023-05-08","kind":"sale","planned":true,"acquired":false,"shares":1125,"price":349,"value":392625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."}],"balance_after":35387,"source":{"system":"sec-edgar","filing":"0001209191-23-028240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123028240/doc4.xml","form_type":"4"}},{"id":349335,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-09T20:10:59.000Z","date":"2023-05-05","kind":"sale","planned":true,"acquired":false,"shares":171,"price":350.3,"value":59901.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $350.30 (range $350.12 to $350.40)."}],"balance_after":36512,"source":{"system":"sec-edgar","filing":"0001209191-23-028240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123028240/doc4.xml","form_type":"4"}},{"id":349334,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-09T20:10:59.000Z","date":"2023-05-05","kind":"sale","planned":true,"acquired":false,"shares":708,"price":349.38,"value":247361.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $349.38 (range $349.00 to $349.95)."}],"balance_after":36683,"source":{"system":"sec-edgar","filing":"0001209191-23-028240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123028240/doc4.xml","form_type":"4"}},{"id":349440,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-03","kind":"sale","planned":true,"acquired":false,"shares":700,"price":351.59,"value":246113.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $351.59 (range $351.33 to $352.02)."}],"balance_after":37391,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":349439,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-03","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":350.53,"value":630954.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $350.53 (range $350.08 to $350.90)."}],"balance_after":38091,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":349438,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-03","kind":"sale","planned":true,"acquired":false,"shares":2008,"price":349.22,"value":701233.76,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $349.22 (range $349.00 to $349.94)."}],"balance_after":39891,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":349437,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":300,"price":353.18,"value":105954.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $353.18 (range $352.63 to $353.53)."}],"balance_after":41899,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":349436,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":1505,"price":350.48,"value":527472.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $350.48 (range $350.08 to $351.01)."}],"balance_after":42199,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":349435,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-05-04T20:50:03.000Z","date":"2023-05-02","kind":"sale","planned":true,"acquired":false,"shares":4645,"price":349.48,"value":1623334.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $349.48 (range $349.00 to $349.99)."}],"balance_after":43704,"source":{"system":"sec-edgar","filing":"0001209191-23-027372","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123027372/doc4.xml","form_type":"4"}},{"id":352328,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-28T21:57:37.000Z","date":"2023-02-24","kind":"tax_withholding","acquired":false,"shares":13730,"price":289.12,"value":3969617.6,"ownership":{"direct":true},"balance_after":48349,"source":{"system":"sec-edgar","filing":"0001209191-23-013728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123013728/doc4.xml","form_type":"4"}},{"id":353528,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-14T22:01:11.000Z","date":"2023-02-13","kind":"tax_withholding","acquired":false,"shares":13344,"price":298.26,"value":3979981.44,"ownership":{"direct":true},"balance_after":62079,"source":{"system":"sec-edgar","filing":"0001209191-23-009211","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123009211/doc4.xml","form_type":"4"}},{"id":354152,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-03T21:53:40.000Z","date":"2023-02-02","kind":"tax_withholding","acquired":false,"shares":3578,"price":317.83,"value":1137195.74,"ownership":{"direct":true},"balance_after":75423,"source":{"system":"sec-edgar","filing":"0001209191-23-006958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006958/doc4.xml","form_type":"4"}},{"id":354151,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-03T21:53:40.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":10226,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":79001,"source":{"system":"sec-edgar","filing":"0001209191-23-006958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006958/doc4.xml","form_type":"4"}},{"id":354150,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-03T21:53:40.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":34890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/24/2023."}],"balance_after":68775,"source":{"system":"sec-edgar","filing":"0001209191-23-006958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006958/doc4.xml","form_type":"4"}},{"id":354149,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2023-02-03T21:53:40.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":31462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023."}],"balance_after":33885,"source":{"system":"sec-edgar","filing":"0001209191-23-006958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919123006958/doc4.xml","form_type":"4"}},{"id":359420,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"exercise","acquired":false,"shares":60342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Fully vested."}],"balance_after":33524,"derivative":{"exercise_price":91.05,"expiration_date":"2026-02-01","underlying":"Common Stock","underlying_shares":60342},"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359419,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":10471,"price":283.42,"value":2967690.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $283.42 (range $282.90 to $283.84)."}],"balance_after":2423,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359418,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":40666,"price":282.43,"value":11485298.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $282.43 (range $281.90 to $282.89)."}],"balance_after":12894,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359417,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":34090,"price":281.27,"value":9588494.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Open market sales reported on this line occurred at a weighted average price of $281.27 (range $280.90 to $281.89)."}],"balance_after":53560,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359416,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":32983,"price":280.37,"value":9247443.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Open market sales reported on this line occurred at a weighted average price of $280.37 (range $279.90 to $280.88)."}],"balance_after":87650,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359415,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"sale","acquired":false,"shares":13869,"price":279.44,"value":3875553.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $279.44 (range $278.90 to $279.89)."}],"balance_after":120633,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":359414,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-07-27T20:17:44.000Z","date":"2022-07-25","kind":"exercise","acquired":true,"shares":60342,"price":91.05,"value":5494139.1,"ownership":{"direct":true},"balance_after":134502,"source":{"system":"sec-edgar","filing":"0000899243-22-026840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322026840/doc4.xml","form_type":"4"}},{"id":362686,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-04-14T20:35:09.000Z","date":"2022-04-13","kind":"sale","acquired":false,"shares":15789,"price":289.04,"value":4563652.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Open market sales reported on this line occurred at a weighted average price of $289.04 (range $289.00 to $289.58)."}],"balance_after":74160,"source":{"system":"sec-edgar","filing":"0000899243-22-014805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322014805/doc4.xml","form_type":"4"}},{"id":365011,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-28T22:23:24.000Z","date":"2022-02-24","kind":"tax_withholding","acquired":false,"shares":12141,"price":227.86,"value":2766448.26,"ownership":{"direct":true},"balance_after":89949,"source":{"system":"sec-edgar","filing":"0000899243-22-008119","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322008119/doc4.xml","form_type":"4"}},{"id":365563,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-22T21:57:56.000Z","date":"2022-02-17","kind":"tax_withholding","acquired":false,"shares":8236,"price":232.51,"value":1914952.36,"ownership":{"direct":true},"balance_after":102090,"source":{"system":"sec-edgar","filing":"0000899243-22-007209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000089924322007209/doc4.xml","form_type":"4"}},{"id":366669,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-03T21:19:24.000Z","date":"2022-02-02","kind":"tax_withholding","acquired":false,"shares":6279,"price":243.63,"value":1529752.77,"ownership":{"direct":true},"balance_after":110326,"source":{"system":"sec-edgar","filing":"0001209191-22-006779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006779/doc4.xml","form_type":"4"}},{"id":366668,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-03T21:19:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":17445,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":116605,"source":{"system":"sec-edgar","filing":"0001209191-22-006779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006779/doc4.xml","form_type":"4"}},{"id":366667,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-03T21:19:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":20928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/17/2022."}],"balance_after":99160,"source":{"system":"sec-edgar","filing":"0001209191-22-006779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006779/doc4.xml","form_type":"4"}},{"id":366666,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2022-02-03T21:19:24.000Z","date":"2022-02-01","kind":"grant","acquired":true,"shares":28444,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022."}],"balance_after":78232,"source":{"system":"sec-edgar","filing":"0001209191-22-006779","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919122006779/doc4.xml","form_type":"4"}},{"id":379878,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-19T21:15:56.000Z","date":"2021-02-17","kind":"tax_withholding","acquired":false,"shares":13970,"price":211.75,"value":2958147.5,"ownership":{"direct":true},"balance_after":49676,"source":{"system":"sec-edgar","filing":"0001209191-21-012344","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121012344/doc4.xml","form_type":"4"}},{"id":380489,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-12T21:10:21.000Z","date":"2021-02-10","kind":"tax_withholding","acquired":false,"shares":13954,"price":214.16,"value":2988388.64,"ownership":{"direct":true},"balance_after":63646,"source":{"system":"sec-edgar","filing":"0001209191-21-010108","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121010108/doc4.xml","form_type":"4"}},{"id":380800,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-05T21:50:28.000Z","date":"2021-02-03","kind":"tax_withholding","acquired":false,"shares":8599,"price":215.03,"value":1849042.97,"ownership":{"direct":true},"balance_after":77600,"source":{"system":"sec-edgar","filing":"0001209191-21-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008126/doc4.xml","form_type":"4"}},{"id":380799,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-05T21:50:28.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":20928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Restricted stock unit award that fully vested upon grant."}],"balance_after":86199,"source":{"system":"sec-edgar","filing":"0001209191-21-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008126/doc4.xml","form_type":"4"}},{"id":380798,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-05T21:50:28.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":31462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/10/2021."}],"balance_after":65271,"source":{"system":"sec-edgar","filing":"0001209191-21-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008126/doc4.xml","form_type":"4"}},{"id":380797,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2021-02-05T21:50:28.000Z","date":"2021-02-03","kind":"grant","acquired":true,"shares":31498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/03/2021 and the shares will vest on 02/17/2021."}],"balance_after":33809,"source":{"system":"sec-edgar","filing":"0001209191-21-008126","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919121008126/doc4.xml","form_type":"4"}},{"id":388663,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-02T20:15:10.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":200,"price":291.34,"value":58268.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Open market sales reported on this line occurred at a weighted average price of $291.34 (range $291.31 to $291.36)."}],"balance_after":2261,"source":{"system":"sec-edgar","filing":"0001209191-20-040271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120040271/doc4.xml","form_type":"4"}},{"id":388662,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-02T20:15:10.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":2534,"price":290.51,"value":736152.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Open market sales reported on this line occurred at a weighted average price of $290.51 (range $290.12 to $290.87)."}],"balance_after":2461,"source":{"system":"sec-edgar","filing":"0001209191-20-040271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120040271/doc4.xml","form_type":"4"}},{"id":388661,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-02T20:15:10.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":500,"price":289.39,"value":144695.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Open market sales reported on this line occurred at a weighted average price of $289.39 (range $289.07 to $289.99)."}],"balance_after":4995,"source":{"system":"sec-edgar","filing":"0001209191-20-040271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120040271/doc4.xml","form_type":"4"}},{"id":388660,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-02T20:15:10.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":1318,"price":287.91,"value":379465.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Open market sales reported on this line occurred at a weighted average price of $287.91 (range $287.75 to $288.16)."}],"balance_after":5495,"source":{"system":"sec-edgar","filing":"0001209191-20-040271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120040271/doc4.xml","form_type":"4"}},{"id":388659,"issuer":{"id":2875,"kind":"organization","name":"VERTEX PHARMACEUTICALS INC / MA","symbol":"VRTX"},"owners":[{"id":14913,"kind":"person","name":"LEIDEN JEFFREY M","position":1,"cik":"0001242825","reported_name":"LEIDEN JEFFREY M","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Chairman"}}],"security":"Common Stock","published_at":"2020-07-02T20:15:10.000Z","date":"2020-06-30","kind":"sale","acquired":false,"shares":4885,"price":287.23,"value":1403118.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.74 to $287.73)."}],"balance_after":6813,"source":{"system":"sec-edgar","filing":"0001209191-20-040271","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/875320/000120919120040271/doc4.xml","form_type":"4"}}],"next_cursor":"2020-07-02T20:15:10.000000Z,388659"}